1. Home
  2. Directory
  3. Indiana
  4. Polis
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1780274613

MATTHEW R DOORE OD
Prescription History 1780274613
Optometrist in Indianapolis, IN


Quality Rating: 79.96 out of 100 score

NPI Status: Active since January 25, 2021

Contact Information

901 E 86TH ST
INDIANAPOLIS, IN
ZIP 46240
Phone: (317) 844-5500
Fax: (317) 208-2248

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MATTHEW R DOORE OD, an active Optometrist specialist practicing in Indianapolis, IN. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 53 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 21 claims alone.

Medication Index

L
P
X
No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 21
30-Day Fills 51.5
Days Supply 1,544
IN State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills234.6
Peer Average Days Supply6,777
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.6% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $385.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.37

State Avg Cost Per Claim

$23.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 18.7
Days Supply 519
IN State Average Benchmarks
Peer Average Claims87.0
Peer Average 30-Day Fills112.8
Peer Average Days Supply2,897
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.8% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $622.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.48

State Avg Cost Per Claim

$49.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.0
Days Supply 630
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,162
Conservative Utilization

This provider writes prescriptions for this formulation 26.1% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,251.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$838.33

State Avg Cost Per Claim

$1,089.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MATTHEW R DOORE OD provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.